FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588754080> ?p ?o ?g. }

• W2588754080 endingPage "631" @default.
• W2588754080 startingPage "625" @default.
• W2588754080 abstract "Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) is a rare but severe complication, with a fulminant clinical onset and a possibly life-threatening outcome that may occur years after a well-tolerated treatment with IFN. Most patients evolve rapidly to advanced chronic kidney disease and eventually to renal failure. We performed a retrospective analysis of TMA cases diagnosed and managed in our Nephrology Department from 2010 to 2015, and performed a literature review of IFN-beta-induced TMA. Three cases of TMA among patients treated with IFN-beta were identified who did not show any renal improvement following conventional therapy: IFN withdrawal and plasma exchange (PE, range 8–18) sessions. All of them responded favourably to eculizumab, with progressive clinical and renal improvement, allowing dialysis discontinuation, without recurrence of TMA during a long-term follow-up (range 1–5 years). TMA is a recognized severe complication in RRMS patients treated with IFN-beta. Withdrawal of IFN and treatment with PE, steroids or rituximab did not improve the poor renal prognosis in our three patients and in all the previously described cases in the literature. In our experience, eculizumab had a strikingly favourable effect on renal recovery, suggesting a role of IFN-beta as a trigger in complement-mediated TMA. Neurologists and nephrologists should be vigilant to this complication to prevent possibly irreversible renal damage." @default.
• W2588754080 created "2017-02-24" @default.
• W2588754080 creator A5009436745 @default.
• W2588754080 creator A5017767151 @default.
• W2588754080 creator A5046530867 @default.
• W2588754080 creator A5047594464 @default.
• W2588754080 creator A5063406481 @default.
• W2588754080 creator A5084897268 @default.
• W2588754080 creator A5087083784 @default.
• W2588754080 date "2017-02-16" @default.
• W2588754080 modified "2023-09-30" @default.
• W2588754080 title "Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab" @default.
• W2588754080 cites W1820363350 @default.
• W2588754080 cites W1926476249 @default.
• W2588754080 cites W1937560614 @default.
• W2588754080 cites W1976230349 @default.
• W2588754080 cites W1995737060 @default.
• W2588754080 cites W1998956477 @default.
• W2588754080 cites W2004939428 @default.
• W2588754080 cites W2005146857 @default.
• W2588754080 cites W2011424232 @default.
• W2588754080 cites W2014155813 @default.
• W2588754080 cites W2021745189 @default.
• W2588754080 cites W2032393221 @default.
• W2588754080 cites W2042961417 @default.
• W2588754080 cites W2044320151 @default.
• W2588754080 cites W2064357278 @default.
• W2588754080 cites W2069107419 @default.
• W2588754080 cites W2073107052 @default.
• W2588754080 cites W2075818946 @default.
• W2588754080 cites W2081434349 @default.
• W2588754080 cites W2082554121 @default.
• W2588754080 cites W2092025726 @default.
• W2588754080 cites W2103803344 @default.
• W2588754080 cites W2109902766 @default.
• W2588754080 cites W2127235095 @default.
• W2588754080 cites W2133416234 @default.
• W2588754080 cites W2136267830 @default.
• W2588754080 cites W2138688863 @default.
• W2588754080 cites W2146452281 @default.
• W2588754080 cites W2152276195 @default.
• W2588754080 cites W2472537117 @default.
• W2588754080 doi "https://doi.org/10.1093/ckj/sfw143" @default.
• W2588754080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5622889" @default.
• W2588754080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28980667" @default.
• W2588754080 hasPublicationYear "2017" @default.
• W2588754080 type Work @default.
• W2588754080 sameAs 2588754080 @default.
• W2588754080 citedByCount "24" @default.
• W2588754080 countsByYear W25887540802018 @default.
• W2588754080 countsByYear W25887540802019 @default.
• W2588754080 countsByYear W25887540802020 @default.
• W2588754080 countsByYear W25887540802021 @default.
• W2588754080 countsByYear W25887540802022 @default.
• W2588754080 countsByYear W25887540802023 @default.
• W2588754080 crossrefType "journal-article" @default.
• W2588754080 hasAuthorship W2588754080A5009436745 @default.
• W2588754080 hasAuthorship W2588754080A5017767151 @default.
• W2588754080 hasAuthorship W2588754080A5046530867 @default.
• W2588754080 hasAuthorship W2588754080A5047594464 @default.
• W2588754080 hasAuthorship W2588754080A5063406481 @default.
• W2588754080 hasAuthorship W2588754080A5084897268 @default.
• W2588754080 hasAuthorship W2588754080A5087083784 @default.
• W2588754080 hasBestOaLocation W25887540801 @default.
• W2588754080 hasConcept C111684460 @default.
• W2588754080 hasConcept C126322002 @default.
• W2588754080 hasConcept C159654299 @default.
• W2588754080 hasConcept C203014093 @default.
• W2588754080 hasConcept C2777878052 @default.
• W2588754080 hasConcept C2777991916 @default.
• W2588754080 hasConcept C2778653478 @default.
• W2588754080 hasConcept C2778715236 @default.
• W2588754080 hasConcept C2779134260 @default.
• W2588754080 hasConcept C2779338263 @default.
• W2588754080 hasConcept C2779978075 @default.
• W2588754080 hasConcept C2780653079 @default.
• W2588754080 hasConcept C54847362 @default.
• W2588754080 hasConcept C71924100 @default.
• W2588754080 hasConcept C81182388 @default.
• W2588754080 hasConcept C90924648 @default.
• W2588754080 hasConceptScore W2588754080C111684460 @default.
• W2588754080 hasConceptScore W2588754080C126322002 @default.
• W2588754080 hasConceptScore W2588754080C159654299 @default.
• W2588754080 hasConceptScore W2588754080C203014093 @default.
• W2588754080 hasConceptScore W2588754080C2777878052 @default.
• W2588754080 hasConceptScore W2588754080C2777991916 @default.
• W2588754080 hasConceptScore W2588754080C2778653478 @default.
• W2588754080 hasConceptScore W2588754080C2778715236 @default.
• W2588754080 hasConceptScore W2588754080C2779134260 @default.
• W2588754080 hasConceptScore W2588754080C2779338263 @default.
• W2588754080 hasConceptScore W2588754080C2779978075 @default.
• W2588754080 hasConceptScore W2588754080C2780653079 @default.
• W2588754080 hasConceptScore W2588754080C54847362 @default.
• W2588754080 hasConceptScore W2588754080C71924100 @default.
• W2588754080 hasConceptScore W2588754080C81182388 @default.
• W2588754080 hasConceptScore W2588754080C90924648 @default.
• W2588754080 hasIssue "5" @default.
• W2588754080 hasLocation W25887540801 @default.

• next